Events  |  Presentations

Presentations

May 2018 Investor Presentation
Phase 3 Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris
Phase 3 Open-label Safety and Patient Satisfaction of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris
Phase 2 Randomized Trial of FMX101, Topical Minocycline Foam, for the Treatment of Acne Vulgaris
Pharmacokinetic Evaluation of FMX101, Topical Minocycline Foam, for the Treatment of Acne Vulgaris
Phase 2 Randomized Trial of FMX103, Topical Minocycline Foam, for the Treatment of Papulopustular Rosacea